Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.
View PricingPakistan's market for vaccines for human medicine is characterized by a reliance on imports to meet domestic demand. From 2020 to 2024, the country sourced the majority of its vaccine imports from a select group of international suppliers, with India, Germany, and China being the most significant. In contrast, Pakistan's own export volume in this sector is minimal, with Sri Lanka being the primary destination. A notable feature of the market is the significant disparity between high import prices and lower export prices, reflecting the value and composition of the traded products. The forecast period to 2035 anticipates continued growth in global vaccine consumption, which will influence Pakistan's import dynamics and pricing structures.
Within the global landscape, vaccine consumption in 2024 was led by China, the United States, and France, which together accounted for 35% of worldwide volume. Other significant consuming nations included India, Poland, Spain, Germany, Japan, Russia, and Indonesia, collectively representing a further 27% of global consumption. On the production side, France maintained its position as the world's largest vaccine producer, accounting for approximately 33% of total output in 2024, a volume that was double that of the second-largest producer, the United States. China held the third position with a 13% share of global production. This context of concentrated production and widespread consumption frames Pakistan's position as a net importer within the international vaccine market.
Pakistan's import supply for vaccines is heavily concentrated. In value terms, the largest suppliers to Pakistan from 2020 to 2024 were India, Germany, and China, which together constituted 67% of total imports. Belgium, the United States, the United Kingdom, and France were other notable sources, together comprising a further 26% of import value. On the export side, Pakistan's foreign sales were minimal in volume, with Sri Lanka emerging as the key destination in value terms.
The price signals for trade were divergent. The average import price for vaccines stood at $104,919 per ton in 2024, marking an increase of 47% against the previous year. This price level demonstrated strong overall expansion throughout the period, having peaked in 2021. Conversely, the average export price from Pakistan was significantly lower at $19,366 per ton in 2024, which represented a notable decline of 43.7% from the previous year. Despite this annual drop, the overall trend for export prices showed modest growth, with a peak reached in 2023.
The global market for vaccines is projected to experience steady growth in consumption leading to 2035, driven by expanding immunization programs, pandemic preparedness initiatives, and the development of new vaccine technologies. This rising global demand is expected to influence Pakistan's market, potentially sustaining high levels of import necessity. The concentrated nature of global production, particularly in countries like France, the United States, and China, suggests that Pakistan will continue to rely on imports from these established hubs and their regional networks, such as India. Import prices are anticipated to remain elevated, reflecting the high value of advanced biological products, though they may be subject to volatility based on global supply dynamics and intellectual property landscapes. Pakistan's export potential in this sector is likely to remain limited in the near to medium term, focused on specific regional partnerships. The significant gap between import and export unit values underscores the country's position within the high-value pharmaceutical supply chain, a structural characteristic expected to persist through the forecast period.
This report provides a comprehensive view of the vaccines industry in Pakistan, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.
Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the vaccines landscape in Pakistan.
The report combines market sizing with trade intelligence and price analytics for Pakistan. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.
This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for Pakistan. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.
The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.
All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.
The forecast horizon extends to 2035 and is based on a structured model that links vaccines demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in Pakistan.
Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.
Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.
Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.
This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of vaccines dynamics in Pakistan.
The market size aggregates consumption and trade data, presented in both value and volume terms.
The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.
Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.
The report benchmarks market size, trade balance, prices, and per-capita indicators for Pakistan.
Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.
Making Data-Driven Decisions to Grow Your Business
A Quick Overview of Market Performance
Understanding the Current State of The Market and its Prospects
Finding New Products to Diversify Your Business
Choosing the Best Countries to Establish Your Sustainable Supply Chain
Choosing the Best Countries to Boost Your Export
The Latest Trends and Insights into The Industry
The Largest Import Supplying Countries
The Largest Destinations for Exports
The Largest Producers on The Market and Their Profiles
An analysis of Q4 results reveals 11 therapeutics companies collectively beat revenue estimates by 7.1%. Moderna outperformed expectations despite a sales drop, and Novavax led the group with the strongest growth.
Analysis of Pfizer and Moderna's post-pandemic challenges, comparing their scale, recent stock performance, and pipeline prospects including Moderna's experimental cancer vaccine and Pfizer's patent expirations.
A 2026 report highlights three healthcare stocks with significant challenges, including declining sales, subscale operations, and weak growth, advising caution for investors.
Capricor Therapeutics reports its Q4 and full-year 2025 financial results, detailing a quarterly net loss of $30.2 million and an annual net loss of $105 million, missing analyst expectations.
Overview of England's ongoing measles case monitoring in 2026, detailing weekly reporting, historical data from 2023-2025, and changes to the publication system.
Moderna shares surged following the resolution of a major patent conflict and a positive European regulatory opinion for its combination flu-COVID vaccine, marking significant progress for the company.
Verified reviewers highlight faster qualification, clearer collaboration, and stronger bid readiness.
High Performer
Regional Grid
High Performer Small-Business
Grid Report
Leader Small-Business
Grid Report
High Performer Mid-Market
Grid Report
Leader
Grid Report
Users Love Us
Milestone badge
Cristian Spataru
Commercial Manager · XTRATECRO
Great for Market Insights and Analysis
“IndexBox is a solid source for trade and industrial market data — what I like best about it is how it aggregates official statistics.”
Review collected and hosted on G2.com.
Juan Pablo Cabrera
Gerente de Innovación · Cartocor
Extremely gratifying
“Access very specific and broad information of any type of market.”
Review collected and hosted on G2.com.
Dilan Salam
GMP; ISO Compliance Supervisor · PiONEER Co. for Pharmaceutical Industries
Powerful data at a fair price
“I have got a lot of benefit from IndexBox, too many data available, and easy to use software at a very good price.”
Review collected and hosted on G2.com.
Counselor Hasan AlKhoori
Founder and CEO · Independent
All the data required
“All the data required for building your full analytics infrastructure.”
Review collected and hosted on G2.com.
Ashenafi Behailu
General Manager · Ashenafi Behailu General Contractor
Detailed, well-organized data
“The data organization and level of detail which it is presented in is very helpful.”
Review collected and hosted on G2.com.
Iman Aref
Senior Export Manager · Padideh Shimi Gharn
Up to date and precise info
“Up to date and precise info, for fulfilling the validity and reliability of the given research.”
Review collected and hosted on G2.com.
Companies list is being prepared. Please check back soon.
Charts mirror the report figures on the platform. Values are synthetic for demo use.
| Top consuming countries | Share, % |
|---|
| Segment | Growth, % |
|---|
| Segment | Kg per capita |
|---|
| Top producing countries | Share, % |
|---|
| Top export price | USD per ton |
|---|
| Top import price | USD per ton |
|---|
| Top importing countries | Share, % |
|---|
| Top import price | USD per ton |
|---|
| Top exporting countries | Share, % |
|---|
| Top export price | USD per ton |
|---|
| Segment | Growth, % |
|---|
| Segment | Growth, % |
|---|
| Product | Rationale |
|---|
Real macro, logistics, and energy indicators are pulled from the IndexBox platform and rendered on demand.
3705
This report provides an in-depth analysis of the global vaccine market.
1982
This report provides an in-depth analysis of the vaccine market in China.
1157
This report provides an in-depth analysis of the vaccine market in the U.S..
983
This report provides an in-depth analysis of the vaccine market in Asia.
977
This report provides an in-depth analysis of the vaccine market in the EU.
3911
This report provides an in-depth analysis of the global antibiotic market.
3645
This report provides an in-depth analysis of the global vitamin market.
3350
This report provides an in-depth analysis of the global antisera market.
2713
This report provides an in-depth analysis of the vitamin market in Iraq.
Instant access. No credit card needed.
Instant access. No credit card needed.
